The World Health Organization Director-General Tedros Adhanom Ghebreyesus said on Friday that WHO’s COVID-19 solidarity trial found Gilead Science’s Remdesivir had no impact on survival rates, adding that it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID-19 treatments.
- WHO’s take on remdesivir leads to more confusion over coronavirus drugs
- Remdesivir not recommended for hospitalized coronavirus patients, WHO says
- Canada reports 2,668 new cases of COVID-19, setting new daily record